DrugWonks on Twitter
Tweets by @PeterPittsDrugWonks on Facebook
CMPI Videos
Video Montage of Third Annual Odyssey Awards Gala Featuring Governor Mitch Daniels, Montel Williams, Dr. Paul Offit and CMPI president Peter Pitts
Indiana Governor Mitch Daniels
Montel Williams, Emmy Award-Winning Talk Show Host
Paul Offit, M.D., Chief of the Division of Infectious Diseases and the Director of the Vaccine Education Center at the Children’s Hospital of Philadelphia, for Leadership in Transformational Medicine
CMPI president Peter J. Pitts
CMPI Web Video: "Science or Celebrity"
Tabloid Medicine
Check Out CMPI's Book
Physician Disempowerment:
A Transatlantic Malaise
Edited By: Peter J. Pitts
Download the E-Book Version Here
A Transatlantic Malaise
Edited By: Peter J. Pitts
Download the E-Book Version Here
CMPI Events
Donate
CMPI Reports
Blog Roll
Alliance for Patient Access
Alternative Health Practice
AHRP
Better Health
BigGovHealth
Biotech Blog
BrandweekNRX
CA Medicine man
Cafe Pharma
Campaign for Modern Medicines
Carlat Psychiatry Blog
Clinical Psychology and Psychiatry: A Closer Look
Conservative's Forum
Club For Growth
CNEhealth.org
Diabetes Mine
Disruptive Women
Doctors For Patient Care
Dr. Gov
Drug Channels
DTC Perspectives
eDrugSearch
Envisioning 2.0
EyeOnFDA
FDA Law Blog
Fierce Pharma
fightingdiseases.org
Fresh Air Fund
Furious Seasons
Gooznews
Gel Health News
Hands Off My Health
Health Business Blog
Health Care BS
Health Care for All
Healthy Skepticism
Hooked: Ethics, Medicine, and Pharma
Hugh Hewitt
IgniteBlog
In the Pipeline
In Vivo
Instapundit
Internet Drug News
Jaz'd Healthcare
Jaz'd Pharmaceutical Industry
Jim Edwards' NRx
Kaus Files
KevinMD
Laffer Health Care Report
Little Green Footballs
Med Buzz
Media Research Center
Medrants
More than Medicine
National Review
Neuroethics & Law
Newsbusters
Nurses For Reform
Nurses For Reform Blog
Opinion Journal
Orange Book
PAL
Peter Rost
Pharm Aid
Pharma Blog Review
Pharma Blogsphere
Pharma Marketing Blog
Pharmablogger
Pharmacology Corner
Pharmagossip
Pharmamotion
Pharmalot
Pharmaceutical Business Review
Piper Report
Polipundit
Powerline
Prescription for a Cure
Public Plan Facts
Quackwatch
Real Clear Politics
Remedyhealthcare
Shark Report
Shearlings Got Plowed
StateHouseCall.org
Taking Back America
Terra Sigillata
The Cycle
The Catalyst
The Lonely Conservative
TortsProf
Town Hall
Washington Monthly
World of DTC Marketing
WSJ Health Blog
AHRP
Better Health
BigGovHealth
Biotech Blog
BrandweekNRX
CA Medicine man
Cafe Pharma
Campaign for Modern Medicines
Carlat Psychiatry Blog
Clinical Psychology and Psychiatry: A Closer Look
Conservative's Forum
Club For Growth
CNEhealth.org
Diabetes Mine
Disruptive Women
Doctors For Patient Care
Dr. Gov
Drug Channels
DTC Perspectives
eDrugSearch
Envisioning 2.0
EyeOnFDA
FDA Law Blog
Fierce Pharma
fightingdiseases.org
Fresh Air Fund
Furious Seasons
Gooznews
Gel Health News
Hands Off My Health
Health Business Blog
Health Care BS
Health Care for All
Healthy Skepticism
Hooked: Ethics, Medicine, and Pharma
Hugh Hewitt
IgniteBlog
In the Pipeline
In Vivo
Instapundit
Internet Drug News
Jaz'd Healthcare
Jaz'd Pharmaceutical Industry
Jim Edwards' NRx
Kaus Files
KevinMD
Laffer Health Care Report
Little Green Footballs
Med Buzz
Media Research Center
Medrants
More than Medicine
National Review
Neuroethics & Law
Newsbusters
Nurses For Reform
Nurses For Reform Blog
Opinion Journal
Orange Book
PAL
Peter Rost
Pharm Aid
Pharma Blog Review
Pharma Blogsphere
Pharma Marketing Blog
Pharmablogger
Pharmacology Corner
Pharmagossip
Pharmamotion
Pharmalot
Pharmaceutical Business Review
Piper Report
Polipundit
Powerline
Prescription for a Cure
Public Plan Facts
Quackwatch
Real Clear Politics
Remedyhealthcare
Shark Report
Shearlings Got Plowed
StateHouseCall.org
Taking Back America
Terra Sigillata
The Cycle
The Catalyst
The Lonely Conservative
TortsProf
Town Hall
Washington Monthly
World of DTC Marketing
WSJ Health Blog
DrugWonks Blog
08/09/2007 08:12 AM |
Our friends at the Abigial Alliance "lose" a round in court but sharpen the debate on access to medicines and exposes a glaring weakness in the FDA's -- and Richard Padzur -- argument about why it shoud keep denying dying patients the right to try experimental drugs....
Dying denied right to unapproved drugs
APPEALS COURT SAYS FAMILIES SHOULD ASK CONGRESS TO ACT
By David G. Savage
Los Angeles Times
WASHINGTON - People who are dying do not have the right to obtain unapproved drugs that are potentially life-saving, even if their doctors say the treatment offers their best hope for survival, a U.S. appeals court in Washington, D.C., ruled Tuesday.
In an 8-2 decision, the court said federal drug regulators are entrusted by law with deciding when new drugs are safe for wide use.
Note the term "wide use." I believe the Abigail Alliance and others can make the case that they are not asking for wide use but targeted, tailored and scientifically responsible use that is consistent with their constitutional rights under the Fifth Amendment. This notion that somehow such rights are trumped by Padzur's effort tot take a wrecking ball to accelerated approval is a joke. The FDA is inconsistent on who gets what and when with respect to access to medicines and I don't think the Supreme Court is going to let this "wide use" nonsense pass particularly since the Alliance is not asking for patients to determine when a product is safe but only to have the FDA create a regulatory pathway for allowing dying patients access.
And let's by clear who the real independent operators are: Padzur is one of those free lancers, along with Graham and the now departed David Ross who acted as a FDA of one under the protection of Waxman and Grassley.
http://www.mercurynews.com/healthandscience/ci_6570788?nclick_check=1 Read More & Comment...
Dying denied right to unapproved drugs
APPEALS COURT SAYS FAMILIES SHOULD ASK CONGRESS TO ACT
By David G. Savage
Los Angeles Times
WASHINGTON - People who are dying do not have the right to obtain unapproved drugs that are potentially life-saving, even if their doctors say the treatment offers their best hope for survival, a U.S. appeals court in Washington, D.C., ruled Tuesday.
In an 8-2 decision, the court said federal drug regulators are entrusted by law with deciding when new drugs are safe for wide use.
Note the term "wide use." I believe the Abigail Alliance and others can make the case that they are not asking for wide use but targeted, tailored and scientifically responsible use that is consistent with their constitutional rights under the Fifth Amendment. This notion that somehow such rights are trumped by Padzur's effort tot take a wrecking ball to accelerated approval is a joke. The FDA is inconsistent on who gets what and when with respect to access to medicines and I don't think the Supreme Court is going to let this "wide use" nonsense pass particularly since the Alliance is not asking for patients to determine when a product is safe but only to have the FDA create a regulatory pathway for allowing dying patients access.
And let's by clear who the real independent operators are: Padzur is one of those free lancers, along with Graham and the now departed David Ross who acted as a FDA of one under the protection of Waxman and Grassley.
http://www.mercurynews.com/healthandscience/ci_6570788?nclick_check=1 Read More & Comment...
08/08/2007 11:55 AM |
The key to is to give consumers in developing countries -- apart from decent public works -- tools and products that make a daily difference in their lives. Which means getting beyond the attack on capitalism and IP. And it means giving entrepreneurs in developing countries capital, reducing regulatory barriers, and promoting distribution of their products globally. It also means retrofitting design specs for medical products so they are affordable.... A combination of cheesecloth, vinegar and a flashlight can be used to detect cervical cancer. This -- a temporary measure until less expensive pap smears are developed -- can be combined with immunizations to reduce cervical cancer worldwide. For instance:
"Officials are already working on a cheaper version of Merck & Co.'s cervical cancer vaccine Gardasil, which currently costs about $360 per dose. Together with stepped-up screening, doctors think that cervical cancer might one day be wiped out as a major health problem for the developing world. Among the places Gardasil is available are the U.S., Europe, Canada, Australia and New Zealand."
Why use the developing world as a political battleground when such approaches can accomplish so much more?
http://www.chron.com/disp/story.mpl/ap/fn/5025324.html Read More & Comment...
"Officials are already working on a cheaper version of Merck & Co.'s cervical cancer vaccine Gardasil, which currently costs about $360 per dose. Together with stepped-up screening, doctors think that cervical cancer might one day be wiped out as a major health problem for the developing world. Among the places Gardasil is available are the U.S., Europe, Canada, Australia and New Zealand."
Why use the developing world as a political battleground when such approaches can accomplish so much more?
http://www.chron.com/disp/story.mpl/ap/fn/5025324.html Read More & Comment...
08/08/2007 07:48 AM |
This week's ruling by the Supreme Court of India institutionalizes that incremental innovation in pharmaceuticals isn't important on the sub-continent -- at least when it comes to patent protection..
Many of the usual suspects (Jamie Love, et al.) applaud this decision. But, in reality, it's a horrible blow to global public health -- and particularly to the Third Word, because economically-driven, short-term decisions have deadly unintended consequences.
As Trevor Jones ( a member of the WHO's Commission on Intellectual Property Rights, Innovation and Public Health) points out relative to treatments for HIV-AIDS:
"Some that are very similar in chemical compositions have been referred to as me-too products, but all the drugs have been vital to the pandemic ... In fact, we need more, not less, me-too products."
The Indian ruling is only the most recent example of how healthcare technology assessment (HTA) aka: evidence-based medicine (EBM) being used to deny not only appropriate patient care, but now case patent protection.
And this is an important link, because minus patent protection, an innovator company can't earn back what it invested in R&D, ergo they can't reinvest their profits in further R&D -- further delaying crucial incremental innovation which is how medical progress is made.
(But large Indian generic manufacturers can make a bundle.)
According to the Center for the Study of Drug Development at Tufts University, only 1 in every 5,000 compounds screened becomes an approved medicine. This means of every 5,000-10,000 compounds tested, only 250 enter pre-clinical testing, five into clinical testing and only one achieves FDA approval. Without financial incentives and intellectual property protection, no company, even ones with the most benevolent motivations, would find it feasible to develop new, innovative, lifesaving and life enhancing-products for consumers.
There are precious few “Eureka!†occasions in healthcare. Progress is made step-by-step, one incremental innovation at a time. And those incremental innovations require extensive research and are expensive. But, boy, are the important. Why? Because that’s how health care progress is made – not through Hollywood-style “Aha!†moments so popular with politicians and pundits – and members of the Indian Supreme Court. Read More & Comment...
Many of the usual suspects (Jamie Love, et al.) applaud this decision. But, in reality, it's a horrible blow to global public health -- and particularly to the Third Word, because economically-driven, short-term decisions have deadly unintended consequences.
As Trevor Jones ( a member of the WHO's Commission on Intellectual Property Rights, Innovation and Public Health) points out relative to treatments for HIV-AIDS:
"Some that are very similar in chemical compositions have been referred to as me-too products, but all the drugs have been vital to the pandemic ... In fact, we need more, not less, me-too products."
The Indian ruling is only the most recent example of how healthcare technology assessment (HTA) aka: evidence-based medicine (EBM) being used to deny not only appropriate patient care, but now case patent protection.
And this is an important link, because minus patent protection, an innovator company can't earn back what it invested in R&D, ergo they can't reinvest their profits in further R&D -- further delaying crucial incremental innovation which is how medical progress is made.
(But large Indian generic manufacturers can make a bundle.)
According to the Center for the Study of Drug Development at Tufts University, only 1 in every 5,000 compounds screened becomes an approved medicine. This means of every 5,000-10,000 compounds tested, only 250 enter pre-clinical testing, five into clinical testing and only one achieves FDA approval. Without financial incentives and intellectual property protection, no company, even ones with the most benevolent motivations, would find it feasible to develop new, innovative, lifesaving and life enhancing-products for consumers.
There are precious few “Eureka!†occasions in healthcare. Progress is made step-by-step, one incremental innovation at a time. And those incremental innovations require extensive research and are expensive. But, boy, are the important. Why? Because that’s how health care progress is made – not through Hollywood-style “Aha!†moments so popular with politicians and pundits – and members of the Indian Supreme Court. Read More & Comment...
08/07/2007 07:23 PM |
Article in my hometown (homestate?) paper on consumers who want Vioxx back for various reasons, none of which are good enough for the "true" voice of the consumer, Consumers Union. The condescending tone of the quote from CU's top doc Marvin Lipman is priceless, but then again, when you are an elitist and think most people are idiots easily manipulated by drug companies except (thank goodness) for you, such egotism can be excused:
"These patients argue they -- and not regulators or lawyers -- should decide whether a drug's benefits outweigh its risks, or even whether a drug poses any risks to them at all.
But Marvin Lipman, chief medical adviser for the nonprofit Consumers Union, which has advocated for drug-safety reforms, said such responses, while not unusual, are misguided.
"People do get used to the idea that one drug can help them," Lipman said. "A person's conviction that something is helping them or that only one thing will help them is often erroneous. The impact may be exaggerated."
As opposed to the CU's conviction that the drugs they recommend as Best Buys for Alzheimer's and other drugs are they only things that will help is not erroneous?
http://www.nj.com/starledger/stories/index.ssf?/base/business-7/1186288491133630.xml&coll=1&thispage=2 Read More & Comment...
"These patients argue they -- and not regulators or lawyers -- should decide whether a drug's benefits outweigh its risks, or even whether a drug poses any risks to them at all.
But Marvin Lipman, chief medical adviser for the nonprofit Consumers Union, which has advocated for drug-safety reforms, said such responses, while not unusual, are misguided.
"People do get used to the idea that one drug can help them," Lipman said. "A person's conviction that something is helping them or that only one thing will help them is often erroneous. The impact may be exaggerated."
As opposed to the CU's conviction that the drugs they recommend as Best Buys for Alzheimer's and other drugs are they only things that will help is not erroneous?
http://www.nj.com/starledger/stories/index.ssf?/base/business-7/1186288491133630.xml&coll=1&thispage=2 Read More & Comment...
08/06/2007 08:16 PM |
Maraviroc would be the first personalized medicine for AIDS because Pfizer would first test patients to determine whether the drug works for them....
http://news.yahoo.com/s/nm/20070806/bs_nm/pfizer_hiv_dc Read More & Comment...
http://news.yahoo.com/s/nm/20070806/bs_nm/pfizer_hiv_dc Read More & Comment...
08/06/2007 11:36 AM |
I don't get all the consternation about Peter Rost becoming a journalist as opposed to a blogger. Let the guy make a steady living. At least, unlike others in the media, he makes his viewpoint known, never gets ruffled and is not afraid to fire back when challenged. I don't agree with him but I will look forward to reading him in his new perch. Good luck to the "other" Peter.
http://www.brandweeknrx.com/2007/08/brandweek-shoul.html Read More & Comment...
http://www.brandweeknrx.com/2007/08/brandweek-shoul.html Read More & Comment...
08/06/2007 10:03 AM |
Lots of posts about whether drugwonks is, because of our "style" less or more credible than it could be...
Our attacks have never been ad hominem. They have been pointed and backed up by facts and informed by frustration. And unlike many of our critics, we read all of the material we blog on, not just the headlines. We actually do research before we post. And when we are wrong or over the line we apologize openly and honestly.
As for our handling of Steve Nissen, he deserves the Derek Lowe-inspired Kevin Trudeau treatment. As we have said several times on this blog -- and no one else in the pharma blog community seems to care, he and his crony Curt Furberg trashed the cardiovascular safety of ADHD drugs in a most unprofessional fashion. Their attack on Avandia has caused many people to stop taking the drug just as Furberg's frivolous and media orchestrated attack on CCB's caused people to stop taking those drugs 10 years ago.
Drugwonks is the only, the only, site that is consistently shining a light on the relationship between so-called activists like Nissen, Furberg, etc., the medical journals, the media, certain members of Congress the damage they have done to the public health with respect to women's health, depression, ADHD and now diabetes. We have criticized Democrats, Republicans, drug companies, drug ads, conservatives, liberals and even Michael Moore.
Moreover, through CMPI we are coming up with constructive, patient-centric approaches to make medicine more personalized and value-based. What we do on drugwonks is a small part of what we do and who we are. As anyone who attended our Medicine and Media program saw, we have many outlets and seek out many approaches to promote science based medicine. Want to ignore that stuff and focus on what we post that annoys the hell out of you? Be my guest. If that makes us less credible, trust me I won't lose any sleep over it.
We are ticking everybody off it seems. So I guess we are doing something write. Read More & Comment...
Our attacks have never been ad hominem. They have been pointed and backed up by facts and informed by frustration. And unlike many of our critics, we read all of the material we blog on, not just the headlines. We actually do research before we post. And when we are wrong or over the line we apologize openly and honestly.
As for our handling of Steve Nissen, he deserves the Derek Lowe-inspired Kevin Trudeau treatment. As we have said several times on this blog -- and no one else in the pharma blog community seems to care, he and his crony Curt Furberg trashed the cardiovascular safety of ADHD drugs in a most unprofessional fashion. Their attack on Avandia has caused many people to stop taking the drug just as Furberg's frivolous and media orchestrated attack on CCB's caused people to stop taking those drugs 10 years ago.
Drugwonks is the only, the only, site that is consistently shining a light on the relationship between so-called activists like Nissen, Furberg, etc., the medical journals, the media, certain members of Congress the damage they have done to the public health with respect to women's health, depression, ADHD and now diabetes. We have criticized Democrats, Republicans, drug companies, drug ads, conservatives, liberals and even Michael Moore.
Moreover, through CMPI we are coming up with constructive, patient-centric approaches to make medicine more personalized and value-based. What we do on drugwonks is a small part of what we do and who we are. As anyone who attended our Medicine and Media program saw, we have many outlets and seek out many approaches to promote science based medicine. Want to ignore that stuff and focus on what we post that annoys the hell out of you? Be my guest. If that makes us less credible, trust me I won't lose any sleep over it.
We are ticking everybody off it seems. So I guess we are doing something write. Read More & Comment...
08/06/2007 08:02 AM |
One of the biggest complaints about DTC pharmaceutical advertising is that it doesn't give patients (aka: consumers) enough information about either the advertised medicine or about the disease under discussion. Now there's a new twist -- consumers (aka: patients) have access to too much information.
In Europe, where there is no pharmaceutical advertising, the debate is about "information to patients," or "ITP."
But no matter what you call it, there's tremendous value in reading a very thought-provoking article in the Baltimore Sun ...
"At a time when more information than ever is broadly available about illnesses and the effects - positive and negative - of the drugs used to treat them, doctors and patients are facing a growing challenge as they attempt to sort out the benefits and risks of medications and therapies.
Every week, professional journals and other sources report the results of new medical studies - a rising tide of information that sometimes seems contradictory. Patients can read the studies on the Internet, or read about them in newspapers, and bombard their doctors with questions that frequently don't have simple answers.
So many patients go on the Internet now and with what the press bombards them with, they have a lot of information. They need to be able to understand the literature, so they can take it to the doctor and ask informed questions, said Erik Rifkin, a retired environmental consultant and co-author of The Illusion of Certainty, a new book that argues for increased clarity in the reporting of medical research.
Rifkin and his co-author, Edward J. Bouwer, both of whom live in Baltimore, say researchers should state findings in terms that are easier to understand. Statistics used in studies - and repeated in news reports - are often misleading, they say."
Here is a link to the article:
http://www.baltimoresun.com/news/health/bal-id.hs.risk05aug05,0,3165339.story
Is more information better? It depends who you ask. According to one patient interviewed for the Sun story, ""I got so much information that I had to quit because with the Internet, there was so much out there." And that was someone searching for information about a condition that predisposed him to cancer.
Too much? Too little? Too complicated? Too simplified?
Too important not to debate and discuss. Read More & Comment...
In Europe, where there is no pharmaceutical advertising, the debate is about "information to patients," or "ITP."
But no matter what you call it, there's tremendous value in reading a very thought-provoking article in the Baltimore Sun ...
"At a time when more information than ever is broadly available about illnesses and the effects - positive and negative - of the drugs used to treat them, doctors and patients are facing a growing challenge as they attempt to sort out the benefits and risks of medications and therapies.
Every week, professional journals and other sources report the results of new medical studies - a rising tide of information that sometimes seems contradictory. Patients can read the studies on the Internet, or read about them in newspapers, and bombard their doctors with questions that frequently don't have simple answers.
So many patients go on the Internet now and with what the press bombards them with, they have a lot of information. They need to be able to understand the literature, so they can take it to the doctor and ask informed questions, said Erik Rifkin, a retired environmental consultant and co-author of The Illusion of Certainty, a new book that argues for increased clarity in the reporting of medical research.
Rifkin and his co-author, Edward J. Bouwer, both of whom live in Baltimore, say researchers should state findings in terms that are easier to understand. Statistics used in studies - and repeated in news reports - are often misleading, they say."
Here is a link to the article:
http://www.baltimoresun.com/news/health/bal-id.hs.risk05aug05,0,3165339.story
Is more information better? It depends who you ask. According to one patient interviewed for the Sun story, ""I got so much information that I had to quit because with the Internet, there was so much out there." And that was someone searching for information about a condition that predisposed him to cancer.
Too much? Too little? Too complicated? Too simplified?
Too important not to debate and discuss. Read More & Comment...
08/05/2007 09:56 AM |
From today's edition of Newsday ...
Lesson from a savvy doctor
BY MARC SIEGEL. Dr. Marc Siegel, an associate professor of medicine at the New York University School of Medicine, is the author of "False Alarm: The Truth About the Epidemic of Fear."
August 5, 2007
You wouldn't know it from the political debate, but health care is much more than just bald statistics about probability, necessity and risk. It is shaped by the quirks and characteristics of its practitioners.
When Dr. Jeffrey Siegel was killed by a hit-and-run motorist and taken last month at age 48 from his life as a prominent Long Island pulmonologist, the world lost a particular sort of physician. Our identities as doctors were molded in the Bellevue Hospital melting pot of the 1980s. He was the Siegel who cooperated; I was the Siegel (no relation) who fought.
Though he was my supervising chief resident for only a few rotations, I remember our clashes, as Jeff Siegel tried to teach me to be more politic and less confrontational. I was often arguing with nurses as well as patients, trying to get my points across, while Jeff was soft-spoken and known to be very persuasive.
Residency training was a cauldron, and as my medical personality was forged I began to learn from Jeff and others that I was often too forceful and that even when a patient's life is on the line it is still possible to negotiate. On the other hand, as I came into my own as a physician I also found that my outrage could help position me as a patient advocate.
Even with all the technology and the growing bottom-line thinking about cost-effective medical care, at the heart of the process are individual doctors who apply their personality traits to patient care. Jeff and I had very different styles, but we shared a tenacity that was essential at a busy city hospital like Bellevue. We were at our best as a team. Even as I was learning to be more politic, he was learning to be more gruff.
Once, a 55-year-old ironworker was admitted to the hospital with a severe heart attack and immediately demanded to leave the same day. As his resident, I was focused on keeping him alive medically.
I was so irritated at his self-destructive refusal of treatment that I began to argue with him relentlessly even as his stretcher was rolling him, still protesting, toward the operating room for cardiac bypass surgery. "You're giving me chest pains," he said, which brought me to my senses as I suddenly realized that I might be jeopardizing his heart further. It took Jeff, as my chief resident, to come by and calmly convince him to agree to the operation.
Afterward, Jeff quietly told me never to raise my voice with a patient, and he left it at that.
The surgery didn't go well, and in the recovery room, as the man's heart ballooned from damage and his lungs continued to fill with fluid, the staff was ready to give up. At which point I erupted in favor of toughing it out, this time directing my blunt insistence not at the patient but at the team working on him. Fortunately, we carried on, and the man's heart began to slowly recover.
I had learned from Jeff that there was little to be gained by yelling at a patient, but I learned for myself there was much to be gained from channeling my strong, stubborn emotions into not giving up. As he recovered, the patient began to see the benefits of my stubbornness on his behalf and grew to like me for it. Of course, he knew that he also owed his life to Jeff's very different intervention. He had strong relationships with both of us, which I am certain helped him get well faster.
Managed care and and health insurance policy arguments can leave us thinking that physicians are just interchangeable, replaceable cogs in a complex machine that doesn't run as well as it used to. Yet the human element remains essential.
Medicine is as much about the developing personalities of those who administer treatment as it is about the technology that measures metabolism. That's the lesson I got from Jeff Siegel's too-short life.
. Read More & Comment...
Lesson from a savvy doctor
BY MARC SIEGEL. Dr. Marc Siegel, an associate professor of medicine at the New York University School of Medicine, is the author of "False Alarm: The Truth About the Epidemic of Fear."
August 5, 2007
You wouldn't know it from the political debate, but health care is much more than just bald statistics about probability, necessity and risk. It is shaped by the quirks and characteristics of its practitioners.
When Dr. Jeffrey Siegel was killed by a hit-and-run motorist and taken last month at age 48 from his life as a prominent Long Island pulmonologist, the world lost a particular sort of physician. Our identities as doctors were molded in the Bellevue Hospital melting pot of the 1980s. He was the Siegel who cooperated; I was the Siegel (no relation) who fought.
Though he was my supervising chief resident for only a few rotations, I remember our clashes, as Jeff Siegel tried to teach me to be more politic and less confrontational. I was often arguing with nurses as well as patients, trying to get my points across, while Jeff was soft-spoken and known to be very persuasive.
Residency training was a cauldron, and as my medical personality was forged I began to learn from Jeff and others that I was often too forceful and that even when a patient's life is on the line it is still possible to negotiate. On the other hand, as I came into my own as a physician I also found that my outrage could help position me as a patient advocate.
Even with all the technology and the growing bottom-line thinking about cost-effective medical care, at the heart of the process are individual doctors who apply their personality traits to patient care. Jeff and I had very different styles, but we shared a tenacity that was essential at a busy city hospital like Bellevue. We were at our best as a team. Even as I was learning to be more politic, he was learning to be more gruff.
Once, a 55-year-old ironworker was admitted to the hospital with a severe heart attack and immediately demanded to leave the same day. As his resident, I was focused on keeping him alive medically.
I was so irritated at his self-destructive refusal of treatment that I began to argue with him relentlessly even as his stretcher was rolling him, still protesting, toward the operating room for cardiac bypass surgery. "You're giving me chest pains," he said, which brought me to my senses as I suddenly realized that I might be jeopardizing his heart further. It took Jeff, as my chief resident, to come by and calmly convince him to agree to the operation.
Afterward, Jeff quietly told me never to raise my voice with a patient, and he left it at that.
The surgery didn't go well, and in the recovery room, as the man's heart ballooned from damage and his lungs continued to fill with fluid, the staff was ready to give up. At which point I erupted in favor of toughing it out, this time directing my blunt insistence not at the patient but at the team working on him. Fortunately, we carried on, and the man's heart began to slowly recover.
I had learned from Jeff that there was little to be gained by yelling at a patient, but I learned for myself there was much to be gained from channeling my strong, stubborn emotions into not giving up. As he recovered, the patient began to see the benefits of my stubbornness on his behalf and grew to like me for it. Of course, he knew that he also owed his life to Jeff's very different intervention. He had strong relationships with both of us, which I am certain helped him get well faster.
Managed care and and health insurance policy arguments can leave us thinking that physicians are just interchangeable, replaceable cogs in a complex machine that doesn't run as well as it used to. Yet the human element remains essential.
Medicine is as much about the developing personalities of those who administer treatment as it is about the technology that measures metabolism. That's the lesson I got from Jeff Siegel's too-short life.
. Read More & Comment...
08/03/2007 08:13 AM |
Have a look at our two new podcasts -- and he beginning of our new "Know Your Pills" campaign.
They can be found at http://www.cmpi.org under the "Special Features/Podcasts" section. Read More & Comment...
They can be found at http://www.cmpi.org under the "Special Features/Podcasts" section. Read More & Comment...
08/02/2007 09:17 AM |
"Sweden’s English-language news outlet reported in June that the government’s employment service had granted Roger Tullgren, 42, supplemental income benefits based on his illness of addiction to heavy-metal music. Tullgren said he had been addicted for 10 years but finally got three psychologists to sign off on calling his condition a disability. His employer now permits Tullgren to play his music at his dishwashing job."
http://www.kansascity.com/238/story/214321.html
I've heard that Zyprexa can be used to wean people off of Megadeth... Read More & Comment...
http://www.kansascity.com/238/story/214321.html
I've heard that Zyprexa can be used to wean people off of Megadeth... Read More & Comment...
08/02/2007 08:50 AM |
Tysabri gets Adcomm approval for Chrohn's disease....now it's time to undo the attack on acccelerated approval of cancer drugs that Padzur is leading.
http://www.forbes.com/business/feeds/afx/2007/08/01/afx3974633.html Read More & Comment...
http://www.forbes.com/business/feeds/afx/2007/08/01/afx3974633.html Read More & Comment...
08/02/2007 08:42 AM |
Here's how the Journal of Life Sciences introduces it's current web-edition cover story on FDA reform:
The FDA needs to rethink the way it communicates in an age of empowered patients.
MUCH HAS CHANGED over the past 25 years, but one of the immutables has been that FDA tries to communicate important health messages without the resources or attitude necessary to do it well on a consistent basis, according to Peter J. Pitts, president of the Center for Medicine in the Public Interest. A big part of the problem is that not only have communications tools changed, but so have people and society. He says the FDA needs to change as well.
Here's the rest of the story:
http://www.tjols.com/index.jsp
And the good news is that Commissioner von Eschenbach believes in strident and robust constituency outreach. Read More & Comment...
The FDA needs to rethink the way it communicates in an age of empowered patients.
MUCH HAS CHANGED over the past 25 years, but one of the immutables has been that FDA tries to communicate important health messages without the resources or attitude necessary to do it well on a consistent basis, according to Peter J. Pitts, president of the Center for Medicine in the Public Interest. A big part of the problem is that not only have communications tools changed, but so have people and society. He says the FDA needs to change as well.
Here's the rest of the story:
http://www.tjols.com/index.jsp
And the good news is that Commissioner von Eschenbach believes in strident and robust constituency outreach. Read More & Comment...
08/02/2007 07:39 AM |
Drug-safety 'advocates'
Earlier this week, a joint session of two Food and Drug Administration advisory committees recommended that Avandia, one of two drugs that reduce insulin resistance, stay on the market with added information about which patients should avoid taking the medicine in order to reduce the risk of heart attacks. The recommendation, based on a careful evaluation of a massive amount of data, focused on whether it was possible to tailor the use of Avandia, which has helped people with diabetes stave off blindness, leg amputations and kidney failure, to groups of patients that might be a higher risk for heart problems.
It remains to be seen whether the measured recommendation puts to rest both the controversy and hysteria surrounding Avandia and the FDA. Dr. Steven Nissen simultaneously released his "study" about Avandia's supposed heart-attack risk and told ABC's "Nightline" that Avandia would kill more people than the September 11 terrorists. Dr. Nissen also shared his data with congressional Democrats and timed his study to come out in advance of the FDA's ongoing review of Avandia, which ultimately proved to be more rigorous, more detailed and more useful in making a decision about clinical use, a decision that ironically mirrors how the drug is being used already.
The fact is, Dr. Nissen and some drug-safety officials at the FDA did nothing to make medicines safer. Rather, their effort is designed to foment fear, politicize science and most immediately gain control over FDA in concert with politicians such as Rep. Henry Waxman and Sen. Charles Grassley. With Avandia, the gimmick was to hype the danger by claiming that meta-analysis, a statistical technique used to cherry-pick and then combine a number of short-term studies, should be the new gold standard for yanking drugs from the market. Such short-term studies were rejected by self-styled FDA whistleblower David Graham and the claims about heart problems associated with Vioxx. Dr. Graham's effort to bolster claims that Avandia could be pulled off the market with safety data on a completely different drug that had not been peer reviewed angered the committee members and exposed Dr. Graham as someone willing to suborn sound science for the sake of power.
It is time to investigate whether these self-proclaimed drug-safety advocates are acting in our best interest.
Nearly 75 percent of diabetes specialists report that their patients on Avandia are concerned, want to go off or have taken themselves off the drug. Many doctors have stopped prescribing or are afraid to prescribe Avandia because of lawsuit concerns. Tort lawyers are using media reports and the Nissen article to build their case against Avandia, though the FDA committee voted to keep it on the market.
Much has been said about the FDA being broken. In truth, those who want to usurp its power have vandalized it. They have undermined the public health and the integrity of medical science. Perhaps the FDA advisory action on Avandia will restore both.
http://www.washingtontimes.com/apps/pbcs.dll/article?AID=/20070802/EDITORIAL/108020002/1013
Thoughts and comments most welcome. Read More & Comment...
Earlier this week, a joint session of two Food and Drug Administration advisory committees recommended that Avandia, one of two drugs that reduce insulin resistance, stay on the market with added information about which patients should avoid taking the medicine in order to reduce the risk of heart attacks. The recommendation, based on a careful evaluation of a massive amount of data, focused on whether it was possible to tailor the use of Avandia, which has helped people with diabetes stave off blindness, leg amputations and kidney failure, to groups of patients that might be a higher risk for heart problems.
It remains to be seen whether the measured recommendation puts to rest both the controversy and hysteria surrounding Avandia and the FDA. Dr. Steven Nissen simultaneously released his "study" about Avandia's supposed heart-attack risk and told ABC's "Nightline" that Avandia would kill more people than the September 11 terrorists. Dr. Nissen also shared his data with congressional Democrats and timed his study to come out in advance of the FDA's ongoing review of Avandia, which ultimately proved to be more rigorous, more detailed and more useful in making a decision about clinical use, a decision that ironically mirrors how the drug is being used already.
The fact is, Dr. Nissen and some drug-safety officials at the FDA did nothing to make medicines safer. Rather, their effort is designed to foment fear, politicize science and most immediately gain control over FDA in concert with politicians such as Rep. Henry Waxman and Sen. Charles Grassley. With Avandia, the gimmick was to hype the danger by claiming that meta-analysis, a statistical technique used to cherry-pick and then combine a number of short-term studies, should be the new gold standard for yanking drugs from the market. Such short-term studies were rejected by self-styled FDA whistleblower David Graham and the claims about heart problems associated with Vioxx. Dr. Graham's effort to bolster claims that Avandia could be pulled off the market with safety data on a completely different drug that had not been peer reviewed angered the committee members and exposed Dr. Graham as someone willing to suborn sound science for the sake of power.
It is time to investigate whether these self-proclaimed drug-safety advocates are acting in our best interest.
Nearly 75 percent of diabetes specialists report that their patients on Avandia are concerned, want to go off or have taken themselves off the drug. Many doctors have stopped prescribing or are afraid to prescribe Avandia because of lawsuit concerns. Tort lawyers are using media reports and the Nissen article to build their case against Avandia, though the FDA committee voted to keep it on the market.
Much has been said about the FDA being broken. In truth, those who want to usurp its power have vandalized it. They have undermined the public health and the integrity of medical science. Perhaps the FDA advisory action on Avandia will restore both.
http://www.washingtontimes.com/apps/pbcs.dll/article?AID=/20070802/EDITORIAL/108020002/1013
Thoughts and comments most welcome. Read More & Comment...
08/02/2007 07:20 AM |
The hypocritcal statements being made by members of Congress about FDA staff bonuses are incredible. Let's set aside the fact that retention bonuses are used throughout governmenet and private sector. It is a well-known and poor reported fact that underpaid hill staffers get bonuses (usually around Christmas time) and that bonuses are often paid to retain the most senior staffers. If I were Dingell or Barton, I would not want someone to investigate how they have doled out bonuses. Read More & Comment...
08/01/2007 04:45 PM |
Not making this one up...
Canadian man rescued after chaining self to tree
Wed Aug 1, 1:19 PM ET
"VANCOUVER, British Columbia (Reuters) - A man has been rescued after he spent nearly a week chained to a tree in a mountain forest near Vancouver in what police believe was a failed suicide attempt.
Hikers searching for a lost dog near the city on Canada's Pacific coast heard the 48-year-old man's calls for help late on Tuesday. They alerted police, who eventually needed a helicopter to pull the man out safety because of the difficult mountain terrain.
West Vancouver Police said the man told them he went to a remote area of the Vancouver suburb six days ago to take his own life and chained himself to the tree in the process.
His injuries were not considered life threatening."
And once again, animals get faster service than humans... Read More & Comment...
Canadian man rescued after chaining self to tree
Wed Aug 1, 1:19 PM ET
"VANCOUVER, British Columbia (Reuters) - A man has been rescued after he spent nearly a week chained to a tree in a mountain forest near Vancouver in what police believe was a failed suicide attempt.
Hikers searching for a lost dog near the city on Canada's Pacific coast heard the 48-year-old man's calls for help late on Tuesday. They alerted police, who eventually needed a helicopter to pull the man out safety because of the difficult mountain terrain.
West Vancouver Police said the man told them he went to a remote area of the Vancouver suburb six days ago to take his own life and chained himself to the tree in the process.
His injuries were not considered life threatening."
And once again, animals get faster service than humans... Read More & Comment...
08/01/2007 02:46 PM |
There has been a lot of talk about how wonderful the Swiss health care system and what a wonderful model it would be for universal health care here in the US. Far be it from me to argue with anyone from the Harvard Business School where all thoughts are patented and original. However, one should consider the following caveats:
1. Health insurance premiums in Switzerland are price controlled and community rated.
2. The benefits package is largely one size fits all and is exceedingly generous with very low deductibles and co-pays.
3. There is little competition on the basis of quality.
4. Hospital costs are paid for largely by federal, state and local authorities.
5. The Swiss system has an any willing provider, fee for service model of care.
6. Dr. Herzlinger makes the same serious mistake those on the Left commit in correlating mortality rates and costs without adjusting for differences in race, age, severity of illness when she writes: "We found lower death rates and spending of only $2,952 per capita versus Connecticut's $4,623. Swiss physicians earn nearly as much as American physicians, and the country has proportionately more expensive resources like MRI machines." So what? And France has more hospitals per capita and doctors get paid way less and similar life expectancy rates as Michael Moore points out. Such comparisons are useless and misleading. The Swiss and French are not like us....
I am not opposed to universal access to health care coverage. But we need a uniquely American response that rewards consumers and recognizes that the real barrier is not so much cost as convenience and education. We need a retail/online model of care not the 19th century model Bismarkian or turn of the century public health model or -- G-d forbid -- the SCHIP model which is just the most inconvenient and uncomfortable form of private health insurance ever invented because it was invented by government. And by the way, the notion that the Swiss model was the light unto the nations is not new. It was first advanced by Peter Zweifel an economist at the University of Zurich. Which is not Harvard. That should tell you that a brand name is sometime is more important than what's being peddled. After all, Aquafina IS just tap water. Read More & Comment...
1. Health insurance premiums in Switzerland are price controlled and community rated.
2. The benefits package is largely one size fits all and is exceedingly generous with very low deductibles and co-pays.
3. There is little competition on the basis of quality.
4. Hospital costs are paid for largely by federal, state and local authorities.
5. The Swiss system has an any willing provider, fee for service model of care.
6. Dr. Herzlinger makes the same serious mistake those on the Left commit in correlating mortality rates and costs without adjusting for differences in race, age, severity of illness when she writes: "We found lower death rates and spending of only $2,952 per capita versus Connecticut's $4,623. Swiss physicians earn nearly as much as American physicians, and the country has proportionately more expensive resources like MRI machines." So what? And France has more hospitals per capita and doctors get paid way less and similar life expectancy rates as Michael Moore points out. Such comparisons are useless and misleading. The Swiss and French are not like us....
I am not opposed to universal access to health care coverage. But we need a uniquely American response that rewards consumers and recognizes that the real barrier is not so much cost as convenience and education. We need a retail/online model of care not the 19th century model Bismarkian or turn of the century public health model or -- G-d forbid -- the SCHIP model which is just the most inconvenient and uncomfortable form of private health insurance ever invented because it was invented by government. And by the way, the notion that the Swiss model was the light unto the nations is not new. It was first advanced by Peter Zweifel an economist at the University of Zurich. Which is not Harvard. That should tell you that a brand name is sometime is more important than what's being peddled. After all, Aquafina IS just tap water. Read More & Comment...
08/01/2007 02:27 PM |
Brain electrodes help man speak again
By MALCOLM RITTER, AP Science Writer
He was beaten and left for dead one night in a robbery while walking home in 1999. His skull was crushed and his brain severely damaged. The doctor said if he pulled through at all, he'd be a vegetable for the rest of his life.
For six years, the man could not speak or eat.
On occasion he showed signs of awareness, and he moved his eyes or a thumb to communicate. His arms were useless. He was fed through a tube.
But researchers chose him for an experimental attempt to rev up his brain by placing electrodes in it. And here's how his mother describes the change in her son, now 38:
"My son can now eat, speak, watch a movie without falling asleep," she said Wednesday while choking back tears during a telephone news conference. "He can drink from a cup. He can express pain. He can cry and he can laugh.
"The most important part is he can say, `Mommy' and `Pop.' He can say, `I love you, Mommy' ... I still cry every time I see my son, but it's tears of joy."
Gee, maybe we should wait until we have randomized clinical trials or some sort of meta analysis before allowing people to have access to such advances once they become commercially available. You know, it might be cheaper just to keep people in a vegetative state because at a $50000 QALY....
I know I am supposed to be constructive and work with the "stakeholders" and all that. But let me just say what a waste of time it all is and to be the first to warn all the patient groups that are sucking up to all the "stakeholders" how they are being used.
http://news.yahoo.com/s/ap/20070801/ap_on_he_me/brain_damage Read More & Comment...
By MALCOLM RITTER, AP Science Writer
He was beaten and left for dead one night in a robbery while walking home in 1999. His skull was crushed and his brain severely damaged. The doctor said if he pulled through at all, he'd be a vegetable for the rest of his life.
For six years, the man could not speak or eat.
On occasion he showed signs of awareness, and he moved his eyes or a thumb to communicate. His arms were useless. He was fed through a tube.
But researchers chose him for an experimental attempt to rev up his brain by placing electrodes in it. And here's how his mother describes the change in her son, now 38:
"My son can now eat, speak, watch a movie without falling asleep," she said Wednesday while choking back tears during a telephone news conference. "He can drink from a cup. He can express pain. He can cry and he can laugh.
"The most important part is he can say, `Mommy' and `Pop.' He can say, `I love you, Mommy' ... I still cry every time I see my son, but it's tears of joy."
Gee, maybe we should wait until we have randomized clinical trials or some sort of meta analysis before allowing people to have access to such advances once they become commercially available. You know, it might be cheaper just to keep people in a vegetative state because at a $50000 QALY....
I know I am supposed to be constructive and work with the "stakeholders" and all that. But let me just say what a waste of time it all is and to be the first to warn all the patient groups that are sucking up to all the "stakeholders" how they are being used.
http://news.yahoo.com/s/ap/20070801/ap_on_he_me/brain_damage Read More & Comment...
08/01/2007 07:41 AM |
According to new IMS data, Medicare Part D has increased sales of cholesterol-lowering statins by 7 percent.
That increase represents more people being appropriately treated for a chronic health problem (in this case hyperlipidemia) that, when appropriately treated, stops them from progressing to more serious acute health conditions (heart attack, stroke, etc.).
And that, dear friends, saves not only lives, but money -- lots of money. This demonstrates once again the prescience of the underlying philosphy behind the MMA -- catch disease early, treat it chronically, reduce acute care costs, enhance and prolong the lives of our citizens. And not necessarily in that order.
And remember, "appropriate" care means the care a physician deems best for the patient -- not "payor permitted" care -- that which is least expensive. Clearly there are many issues at stake here, not the least of which is forced switching of medicines such as (yes, you guessed it) statins.
The facts, the evidence is becoming clearer every day -- "cost-centric" care is penny-wise and pound foolish when compared to "patient-centric" care -- the real evidence-based medicine. Read More & Comment...
That increase represents more people being appropriately treated for a chronic health problem (in this case hyperlipidemia) that, when appropriately treated, stops them from progressing to more serious acute health conditions (heart attack, stroke, etc.).
And that, dear friends, saves not only lives, but money -- lots of money. This demonstrates once again the prescience of the underlying philosphy behind the MMA -- catch disease early, treat it chronically, reduce acute care costs, enhance and prolong the lives of our citizens. And not necessarily in that order.
And remember, "appropriate" care means the care a physician deems best for the patient -- not "payor permitted" care -- that which is least expensive. Clearly there are many issues at stake here, not the least of which is forced switching of medicines such as (yes, you guessed it) statins.
The facts, the evidence is becoming clearer every day -- "cost-centric" care is penny-wise and pound foolish when compared to "patient-centric" care -- the real evidence-based medicine. Read More & Comment...
07/31/2007 09:44 PM |
"The fact that the National Health Service — the "envy of the world" in every British politician's absurdly parochial cliché — has to hire Wahhabist doctors with no background checks tells you everything about where the country's heading..."
http://www.steynonline.com/content/view/405/ Read More & Comment...
http://www.steynonline.com/content/view/405/ Read More & Comment...
Social Networks
Please Follow the Drugwonks Blog on Facebook, Twitter, LinkedIn, YouTube & RSS
Add This Blog to my Technorati Favorites